ea0098c32 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023
Trikalinos, MD Nikolaos
, De La Iglesia, MD Michael
, Prasad MD, PhD Vikas
, Amin, MD Manik
, Winter, BSN, RN Kyle
, Schutte MSN, FNP-C, AOCNP Justin
, Kim, MD Hyun
Background: Peptide receptor radionuclide therapy (PRRT) was introduced in 2018 as one of the major advances in treatment of patients with neuroendocrine neoplasms (NENs). Initial results from the NETTER-1 trial suggested a very low percentage of secondary hematological malignancies, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). We sought to confirm that data in a large institutional database. Methods: Under an institutio...